ID   RIPR2_HUMAN             Reviewed;        1068 AA.
AC   Q9Y4F9; A6NHP2; Q13529; Q5VV37; Q5VV38; Q9BQ28;
DT   29-MAY-2007, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 4.
DT   28-JUN-2023, entry version 157.
DE   RecName: Full=Rho family-interacting cell polarization regulator 2;
GN   Name=RIPOR2;
GN   Synonyms=C6orf32, DIFF48, FAM65B, KIAA0386, PL48
GN   {ECO:0000303|PubMed:9055809};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), TISSUE SPECIFICITY, AND INDUCTION.
RC   TISSUE=Placenta;
RX   PubMed=9055809; DOI=10.1016/s0378-1119(96)00587-2;
RA   Dakour J., Li H., Morrish D.W.;
RT   "PL48: a novel gene associated with cytotrophoblast and lineage-specific
RT   HL-60 cell differentiation.";
RL   Gene 185:153-157(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS MET-320
RP   AND GLN-868.
RC   TISSUE=Brain;
RX   PubMed=9205841; DOI=10.1093/dnares/4.2.141;
RA   Nagase T., Ishikawa K., Nakajima D., Ohira M., Seki N., Miyajima N.,
RA   Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. VII. The
RT   complete sequences of 100 new cDNA clones from brain which can code for
RT   large proteins in vitro.";
RL   DNA Res. 4:141-150(1997).
RN   [3]
RP   SEQUENCE REVISION.
RA   Ohara O., Nagase T., Kikuno R., Nomura N.;
RL   Submitted (JAN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION (ISOFORM 2), TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND DOMAIN.
RX   PubMed=17150207; DOI=10.1016/j.ydbio.2006.11.002;
RA   Yoon S., Molloy M.J., Wu M.P., Cowan D.B., Gussoni E.;
RT   "C6ORF32 is upregulated during muscle cell differentiation and induces the
RT   formation of cellular filopodia.";
RL   Dev. Biol. 301:70-81(2007).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=T-cell;
RX   PubMed=19367720; DOI=10.1021/pr800500r;
RA   Carrascal M., Ovelleiro D., Casas V., Gay M., Abian J.;
RT   "Phosphorylation analysis of primary human T lymphocytes using sequential
RT   IMAC and titanium oxide enrichment.";
RL   J. Proteome Res. 7:5167-5176(2008).
RN   [9]
RP   FUNCTION, INTERACTION WITH RHOA (ISOFORMS 1 AND 2), SUBCELLULAR LOCATION,
RP   TISSUE SPECIFICITY, AND INDUCTION (ISOFORMS 1 AND 2).
RX   PubMed=23241886; DOI=10.4049/jimmunol.1201174;
RA   Rougerie P., Largeteau Q., Megrelis L., Carrette F., Lejeune T.,
RA   Toffali L., Rossi B., Zeghouf M., Cherfils J., Constantin G., Laudanna C.,
RA   Bismuth G., Mangeney M., Delon J.;
RT   "Fam65b is a new transcriptional target of FOXO1 that regulates RhoA
RT   signaling for T lymphocyte migration.";
RL   J. Immunol. 190:748-755(2013).
RN   [10]
RP   FUNCTION, TISSUE SPECIFICITY, ACETYLATION, SUBCELLULAR LOCATION,
RP   INTERACTION WITH 14-3-3 PROTEINS; HDAC6; DYSF AND MYOF, AND INDUCTION.
RX   PubMed=24687993; DOI=10.1096/fj.13-246470;
RA   Balasubramanian A., Kawahara G., Gupta V.A., Rozkalne A., Beauvais A.,
RA   Kunkel L.M., Gussoni E.;
RT   "Fam65b is important for formation of the HDAC6-dysferlin protein complex
RT   during myogenic cell differentiation.";
RL   FASEB J. 28:2955-2969(2014).
RN   [11]
RP   FUNCTION, AND INVOLVEMENT IN DFNB104.
RX   PubMed=24958875; DOI=10.1073/pnas.1401950111;
RA   Diaz-Horta O., Subasioglu-Uzak A., Grati M., DeSmidt A., Foster J., Cao L.,
RA   Bademci G., Tokgoz-Yilmaz S., Duman D., Cengiz F.B., Abad C., Mittal R.,
RA   Blanton S., Liu X.Z., Farooq A., Walz K., Lu Z., Tekin M.;
RT   "FAM65B is a membrane-associated protein of hair cell stereocilia required
RT   for hearing.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:9864-9868(2014).
RN   [12]
RP   FUNCTION (ISOFORM 2), INTERACTION WITH 14-3-3 PROTEINS; RHOA; YWHAB; YWHAE
RP   AND YWHAQ (ISOFORM 2), PHOSPHORYLATION AT SER-21; SER-37; SER-341; SER-523
RP   AND SER-585 (ISOFORM 2), SUBCELLULAR LOCATION (ISOFORM 2), MUTAGENESIS OF
RP   SER-21; SER-37; 151-ARG-LEU-152; 155-GLY-ALA-156; SER-341; SER-523 AND
RP   SER-585, AND IDENTIFICATION BY MASS SPECTROMETRY (ISOFORM 2).
RX   PubMed=25588844; DOI=10.1242/jcs.161497;
RA   Gao K., Tang W., Li Y., Zhang P., Wang D., Yu L., Wang C., Wu D.;
RT   "Front-signal-dependent accumulation of the RHOA inhibitor FAM65B at
RT   leading edges polarizes neutrophils.";
RL   J. Cell Sci. 128:992-1000(2015).
RN   [13]
RP   FUNCTION (ISOFORM 2), INTERACTION WITH 14-3-3 PROTEINS AND HDAC6 (ISOFORM
RP   2), PHOSPHORYLATION (ISOFORM 2), MUTAGENESIS OF SER-21; SER-37;
RP   151-ARG-LEU-152; SER-341; SER-523 AND SER-585, INDUCTION (ISOFORMS 1 AND
RP   2), AND TISSUE SPECIFICITY.
RX   PubMed=27556504; DOI=10.18632/oncotarget.11438;
RA   Froehlich J., Versapuech M., Megrelis L., Largeteau Q., Meunier S.,
RA   Tanchot C., Bismuth G., Delon J., Mangeney M.;
RT   "FAM65B controls the proliferation of transformed and primary T cells.";
RL   Oncotarget 7:63215-63225(2016).
RN   [14]
RP   INVOLVEMENT IN DFNA21, VARIANT DFNA21 566-GLN--LYS-569 DEL, AND
RP   CHARACTERIZATION OF VARIANT DFNA21 566-GLN--LYS-569 DEL.
RX   PubMed=32631815; DOI=10.1136/jmedgenet-2020-106863;
RA   de Bruijn S.E., Smits J.J., Liu C., Lanting C.P., Beynon A.J.,
RA   Blankevoort J., Oostrik J., Koole W., de Vrieze E., Cremers C.W.R.J.,
RA   Cremers F.P.M., Roosing S., Yntema H.G., Kunst H.P.M., Zhao B.,
RA   Pennings R.J.E., Kremer H.;
RT   "A RIPOR2 in-frame deletion is a frequent and highly penetrant cause of
RT   adult-onset hearing loss.";
RL   J. Med. Genet. 0:0-0(2020).
CC   -!- FUNCTION: Acts as an inhibitor of the small GTPase RHOA and plays
CC       several roles in the regulation of myoblast and hair cell
CC       differentiation, lymphocyte T proliferation and neutrophil polarization
CC       (PubMed:17150207, PubMed:24687993, PubMed:23241886, PubMed:24958875,
CC       PubMed:25588844, PubMed:27556504). Inhibits chemokine-induced T
CC       lymphocyte responses, such as cell adhesion, polarization and migration
CC       (PubMed:23241886). Involved also in the regulation of neutrophil
CC       polarization, chemotaxis and adhesion (By similarity). Required for
CC       normal development of inner and outer hair cell stereocilia within the
CC       cochlea of the inner ear (By similarity). Plays a role for maintaining
CC       the structural organization of the basal domain of stereocilia (By
CC       similarity). Involved in mechanosensory hair cell function (By
CC       similarity). Required for normal hearing (PubMed:24958875).
CC       {ECO:0000250|UniProtKB:Q80U16, ECO:0000269|PubMed:17150207,
CC       ECO:0000269|PubMed:23241886, ECO:0000269|PubMed:24687993,
CC       ECO:0000269|PubMed:24958875, ECO:0000269|PubMed:27556504}.
CC   -!- FUNCTION: [Isoform 2]: Acts as an inhibitor of the small GTPase RHOA
CC       (PubMed:25588844). Plays a role in fetal mononuclear myoblast
CC       differentiation by promoting filopodia and myotube formation
CC       (PubMed:17150207). Maintains naive T lymphocytes in a quiescent state
CC       (PubMed:27556504). {ECO:0000269|PubMed:17150207,
CC       ECO:0000269|PubMed:25588844, ECO:0000269|PubMed:27556504}.
CC   -!- SUBUNIT: Homooligomer; homooligomerization is regulated by RHOC and
CC       leads to the formation of concatemers through the association of N- and
CC       C-termini (By similarity). Interacts with 14-3-3 proteins; these
CC       interactions occur during myogenic cell differentiation
CC       (PubMed:24687993). Interacts with HDAC6; this interaction occurs during
CC       early myogenic differentiation and prevents HDAC6 to deacetylate
CC       tubulin (PubMed:24687993). Interacts with DYSF; this interaction occurs
CC       during early myogenic differentiation (PubMed:24687993). Interacts with
CC       MYOF (PubMed:24687993). Interacts with RHOC (By similarity). Isoform 1
CC       and isoform 2 interact (via active GTP- or inactive GDP-bound forms)
CC       with RHOA; these interactions are direct, block the loading of GTP to
CC       RHOA and decrease upon chemokine CCL19 stimulation in primary T
CC       lymphocytes (PubMed:23241886, PubMed:25588844). Isoform 2 interacts
CC       (phosphorylated form) with HDAC6; this interaction induces T cell
CC       proliferation arrest (PubMed:27556504). Isoform 2 interacts
CC       (phosphorylated form) with 14-3-3 proteins; these interactions induces
CC       T cell proliferation arrest (PubMed:27556504). Isoform 2 interacts with
CC       14-3-3 proteins (PubMed:25588844). Isoform 2 interacts (via
CC       phosphorylated form) with YWHAB; this interaction occurs in a
CC       chemokine-dependent manner and does not compete for binding of RIPOR2
CC       with RHOA nor blocks inhibition of RIPOR2-mediated RHOA activity
CC       (PubMed:25588844). Isoform 2 interacts with YWHAE (PubMed:25588844).
CC       Isoform 2 interacts with YWHAQ (PubMed:25588844).
CC       {ECO:0000250|UniProtKB:Q80U16, ECO:0000269|PubMed:23241886,
CC       ECO:0000269|PubMed:24687993, ECO:0000269|PubMed:25588844,
CC       ECO:0000269|PubMed:27556504}.
CC   -!- INTERACTION:
CC       Q9Y4F9; P61586: RHOA; NbExp=4; IntAct=EBI-2798942, EBI-446668;
CC       Q9Y4F9; P08134: RHOC; NbExp=5; IntAct=EBI-2798942, EBI-747589;
CC       Q9Y4F9-2; P61586: RHOA; NbExp=3; IntAct=EBI-14509742, EBI-446668;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17150207,
CC       ECO:0000269|PubMed:23241886}. Cytoplasm, cytoskeleton
CC       {ECO:0000269|PubMed:17150207}. Cell projection, filopodium
CC       {ECO:0000269|PubMed:17150207}. Cell projection, stereocilium
CC       {ECO:0000250|UniProtKB:Q80U16}. Cell projection, stereocilium membrane
CC       {ECO:0000250|UniProtKB:Q7TP54}. Apical cell membrane
CC       {ECO:0000250|UniProtKB:Q7TP54}. Note=Localized in the cytoplasm in
CC       cells undergoing mitosis (PubMed:17150207). Colocalized with F-actin
CC       (PubMed:17150207). Localized with RHOC within the basal domain of hair
CC       cell stereocilia, near the taper region (By similarity). Detected in
CC       punctate pattern forming a circumferential ring at the stereocilia base
CC       (By similarity). Localized to the apical stereocilia of inner and outer
CC       hair cells (By similarity). Not detected as a membrane-associated
CC       protein in stereocilia (By similarity). {ECO:0000250|UniProtKB:Q7TP54,
CC       ECO:0000250|UniProtKB:Q80U16, ECO:0000269|PubMed:17150207}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Cytoplasm
CC       {ECO:0000269|PubMed:24687993}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Cytoplasm
CC       {ECO:0000269|PubMed:25588844}. Note=Accumulates at the leading edge of
CC       polarized neutrophils in a chemokine-dependent manner
CC       (PubMed:25588844). {ECO:0000269|PubMed:25588844}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9Y4F9-1; Sequence=Displayed;
CC       Name=2; Synonyms=PL48 {ECO:0000303|PubMed:9055809};
CC         IsoId=Q9Y4F9-2; Sequence=VSP_025904, VSP_025905, VSP_025906;
CC   -!- TISSUE SPECIFICITY: Expressed in primary fetal mononuclear myoblast
CC       (PubMed:17150207). Expressed strongly in naive T lymphocytes
CC       (PubMed:27556504). Expressed weakly in activated T lymphocytes (at
CC       protein level) (PubMed:27556504). Expressed in blood cells and adult
CC       tissues of hematopoietic origin, such as the secondary lymphoid organs
CC       (PubMed:23241886). Expressed in cytotrophoblast (PubMed:9055809).
CC       {ECO:0000269|PubMed:17150207, ECO:0000269|PubMed:23241886,
CC       ECO:0000269|PubMed:27556504, ECO:0000269|PubMed:9055809}.
CC   -!- INDUCTION: Up-regulated during fetal mononuclear myoblast
CC       differentiation (PubMed:17150207, PubMed:24687993). Up-regulated during
CC       cytotrophoblast differentiation (PubMed:9055809). Up-regulated during
CC       granulocyte differentiation (PubMed:9055809). Isoform 1 and isoform 2
CC       are down-regulated in T lymphocytes upon T-cell antigen receptor (TCR)
CC       stimulation (PubMed:27556504). Isoform 1 and isoform 2 are up-regulated
CC       by FOXO1 (PubMed:23241886). {ECO:0000269|PubMed:17150207,
CC       ECO:0000269|PubMed:23241886, ECO:0000269|PubMed:24687993,
CC       ECO:0000269|PubMed:27556504, ECO:0000269|PubMed:9055809}.
CC   -!- PTM: Phosphorylated. Isoform 2 is phosphorylated in T cells
CC       (PubMed:27556504). Chemokine-induced phosphorylation of isoform 2 in
CC       neutrophils occurs in a PKC- and AKT-dependent manner, resulting in
CC       RIPOR2 interaction with YWHAB and stabilization (PubMed:25588844).
CC       Isoform 2 is phosphorylated by PKCA, AKT1 and MAPKAPK1A; in vitro
CC       (PubMed:25588844). {ECO:0000269|PubMed:25588844,
CC       ECO:0000269|PubMed:27556504}.
CC   -!- PTM: Acetylated during myogenic differentiation.
CC       {ECO:0000269|PubMed:24687993}.
CC   -!- DISEASE: Deafness, autosomal recessive, 104 (DFNB104) [MIM:616515]: A
CC       form of non-syndromic sensorineural hearing loss. Sensorineural
CC       deafness results from damage to the neural receptors of the inner ear,
CC       the nerve pathways to the brain, or the area of the brain that receives
CC       sound information. {ECO:0000269|PubMed:24958875}. Note=The disease is
CC       caused by variants affecting the gene represented in this entry.
CC   -!- DISEASE: Deafness, autosomal dominant, 21 (DFNA21) [MIM:607017]: A form
CC       of non-syndromic sensorineural hearing loss. Sensorineural deafness
CC       results from damage to the neural receptors of the inner ear, the nerve
CC       pathways to the brain, or the area of the brain that receives sound
CC       information. DFNA21 is an autosomal dominant, progressive form with
CC       incomplete penetrance. Age at onset ranges from infancy to late
CC       adulthood. {ECO:0000269|PubMed:32631815}. Note=The disease is caused by
CC       variants affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Cells lacking isoform 2 exhibit a severe reduction of
CC       myotube formation. In contrast, isoform 2 overexpression induces
CC       formation of filopodia.
CC   -!- SIMILARITY: Belongs to the RIPOR family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC51134.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=BAA20840.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U49187; AAC51134.1; ALT_FRAME; mRNA.
DR   EMBL; AB002384; BAA20840.2; ALT_INIT; mRNA.
DR   EMBL; AL512428; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL078584; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471087; EAW55470.1; -; Genomic_DNA.
DR   EMBL; BC001232; AAH01232.1; -; mRNA.
DR   CCDS; CCDS47383.1; -. [Q9Y4F9-1]
DR   CCDS; CCDS47384.1; -. [Q9Y4F9-2]
DR   RefSeq; NP_001273375.1; NM_001286446.2.
DR   RefSeq; NP_001273376.1; NM_001286447.1.
DR   RefSeq; NP_055537.2; NM_014722.4. [Q9Y4F9-1]
DR   RefSeq; NP_056948.2; NM_015864.3. [Q9Y4F9-2]
DR   RefSeq; XP_016867015.1; XM_017011526.1.
DR   RefSeq; XP_016867016.1; XM_017011527.1.
DR   AlphaFoldDB; Q9Y4F9; -.
DR   BioGRID; 115098; 11.
DR   IntAct; Q9Y4F9; 10.
DR   STRING; 9606.ENSP00000482957; -.
DR   GlyCosmos; Q9Y4F9; 1 site, 1 glycan.
DR   GlyGen; Q9Y4F9; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q9Y4F9; -.
DR   PhosphoSitePlus; Q9Y4F9; -.
DR   BioMuta; RIPOR2; -.
DR   DMDM; 296439477; -.
DR   EPD; Q9Y4F9; -.
DR   jPOST; Q9Y4F9; -.
DR   MassIVE; Q9Y4F9; -.
DR   MaxQB; Q9Y4F9; -.
DR   PaxDb; Q9Y4F9; -.
DR   PeptideAtlas; Q9Y4F9; -.
DR   ProteomicsDB; 86200; -. [Q9Y4F9-1]
DR   ProteomicsDB; 86201; -. [Q9Y4F9-2]
DR   Antibodypedia; 25358; 186 antibodies from 26 providers.
DR   DNASU; 9750; -.
DR   Ensembl; ENST00000259698.9; ENSP00000259698.4; ENSG00000111913.20. [Q9Y4F9-1]
DR   Ensembl; ENST00000378023.8; ENSP00000367262.4; ENSG00000111913.20. [Q9Y4F9-2]
DR   Ensembl; ENST00000613507.4; ENSP00000482957.1; ENSG00000111913.20. [Q9Y4F9-1]
DR   Ensembl; ENST00000643623.1; ENSP00000495245.1; ENSG00000111913.20. [Q9Y4F9-2]
DR   Ensembl; ENST00000644621.1; ENSP00000495914.1; ENSG00000111913.20. [Q9Y4F9-2]
DR   GeneID; 9750; -.
DR   KEGG; hsa:9750; -.
DR   UCSC; uc003neo.3; human. [Q9Y4F9-1]
DR   AGR; HGNC:13872; -.
DR   CTD; 9750; -.
DR   DisGeNET; 9750; -.
DR   GeneCards; RIPOR2; -.
DR   HGNC; HGNC:13872; RIPOR2.
DR   HPA; ENSG00000111913; Tissue enhanced (lymphoid).
DR   MalaCards; RIPOR2; -.
DR   MIM; 607017; phenotype.
DR   MIM; 611410; gene.
DR   MIM; 616515; phenotype.
DR   neXtProt; NX_Q9Y4F9; -.
DR   OpenTargets; ENSG00000111913; -.
DR   Orphanet; 90636; Autosomal recessive non-syndromic sensorineural deafness type DFNB.
DR   PharmGKB; PA162387677; -.
DR   VEuPathDB; HostDB:ENSG00000111913; -.
DR   eggNOG; ENOG502QQ7T; Eukaryota.
DR   GeneTree; ENSGT00940000153717; -.
DR   HOGENOM; CLU_432085_0_0_1; -.
DR   InParanoid; Q9Y4F9; -.
DR   OrthoDB; 2909587at2759; -.
DR   PhylomeDB; Q9Y4F9; -.
DR   TreeFam; TF329332; -.
DR   PathwayCommons; Q9Y4F9; -.
DR   Reactome; R-HSA-9662360; Sensory processing of sound by inner hair cells of the cochlea.
DR   Reactome; R-HSA-9662361; Sensory processing of sound by outer hair cells of the cochlea.
DR   SignaLink; Q9Y4F9; -.
DR   BioGRID-ORCS; 9750; 7 hits in 1145 CRISPR screens.
DR   ChiTaRS; FAM65B; human.
DR   GenomeRNAi; 9750; -.
DR   Pharos; Q9Y4F9; Tbio.
DR   PRO; PR:Q9Y4F9; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; Q9Y4F9; protein.
DR   Bgee; ENSG00000111913; Expressed in blood and 165 other tissues.
DR   ExpressionAtlas; Q9Y4F9; baseline and differential.
DR   Genevisible; Q9Y4F9; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005856; C:cytoskeleton; IDA:UniProtKB.
DR   GO; GO:0030175; C:filopodium; IDA:UniProtKB.
DR   GO; GO:0032420; C:stereocilium; ISS:UniProtKB.
DR   GO; GO:0060171; C:stereocilium membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0071889; F:14-3-3 protein binding; IDA:UniProtKB.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW.
DR   GO; GO:1990869; P:cellular response to chemokine; IDA:UniProtKB.
DR   GO; GO:0006935; P:chemotaxis; IEA:UniProtKB-KW.
DR   GO; GO:0007517; P:muscle organ development; IEA:UniProtKB-KW.
DR   GO; GO:0007162; P:negative regulation of cell adhesion; IMP:UniProtKB.
DR   GO; GO:1903904; P:negative regulation of establishment of T cell polarity; IMP:UniProtKB.
DR   GO; GO:1905872; P:negative regulation of protein localization to cell leading edge; ISS:UniProtKB.
DR   GO; GO:2001107; P:negative regulation of Rho guanyl-nucleotide exchange factor activity; IMP:UniProtKB.
DR   GO; GO:0035024; P:negative regulation of Rho protein signal transduction; IMP:UniProtKB.
DR   GO; GO:2000405; P:negative regulation of T cell migration; IMP:UniProtKB.
DR   GO; GO:0042130; P:negative regulation of T cell proliferation; IMP:UniProtKB.
DR   GO; GO:0051491; P:positive regulation of filopodium assembly; IMP:UniProtKB.
DR   GO; GO:0045663; P:positive regulation of myoblast differentiation; IMP:UniProtKB.
DR   GO; GO:1901741; P:positive regulation of myoblast fusion; IMP:UniProtKB.
DR   GO; GO:0090023; P:positive regulation of neutrophil chemotaxis; ISS:UniProtKB.
DR   GO; GO:2000391; P:positive regulation of neutrophil extravasation; ISS:UniProtKB.
DR   GO; GO:0051726; P:regulation of cell cycle; IMP:UniProtKB.
DR   GO; GO:2000114; P:regulation of establishment of cell polarity; ISS:UniProtKB.
DR   GO; GO:1901673; P:regulation of mitotic spindle assembly; IMP:UniProtKB.
DR   GO; GO:0007605; P:sensory perception of sound; IMP:UniProtKB.
DR   Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 1.
DR   InterPro; IPR011989; ARM-like.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR031780; FAM65_N.
DR   InterPro; IPR026136; RIPOR3.
DR   PANTHER; PTHR15829; PROTEIN KINASE PKN/PRK1, EFFECTOR; 1.
DR   PANTHER; PTHR15829:SF2; RHO FAMILY-INTERACTING CELL POLARIZATION REGULATOR 2; 1.
DR   Pfam; PF15903; PL48; 1.
DR   SUPFAM; SSF48371; ARM repeat; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell adhesion; Cell membrane; Cell projection;
KW   Chemotaxis; Coiled coil; Cytoplasm; Cytoskeleton; Deafness;
KW   Developmental protein; Differentiation; Disease variant; Hearing; Membrane;
KW   Myogenesis; Non-syndromic deafness; Phosphoprotein; Reference proteome;
KW   Signal transduction inhibitor.
FT   CHAIN           1..1068
FT                   /note="Rho family-interacting cell polarization regulator
FT                   2"
FT                   /id="PRO_0000289114"
FT   REGION          45..73
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          55..113
FT                   /note="Involved in cell filopodia formation"
FT                   /evidence="ECO:0000269|PubMed:17150207"
FT   REGION          474..524
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          83..112
FT                   /evidence="ECO:0000255"
FT   COILED          768..793
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        474..493
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        494..514
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         21
FT                   /note="Phosphoserine; in isoform 2"
FT                   /evidence="ECO:0000269|PubMed:25588844"
FT   MOD_RES         37
FT                   /note="Phosphoserine; in isoform 2"
FT                   /evidence="ECO:0000269|PubMed:25588844"
FT   MOD_RES         341
FT                   /note="Phosphoserine; in isoform 2"
FT                   /evidence="ECO:0000269|PubMed:25588844"
FT   MOD_RES         523
FT                   /note="Phosphoserine; in isoform 2"
FT                   /evidence="ECO:0000269|PubMed:25588844"
FT   MOD_RES         573
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80U16"
FT   MOD_RES         585
FT                   /note="Phosphoserine; in isoform 2"
FT                   /evidence="ECO:0000269|PubMed:25588844"
FT   VAR_SEQ         360..409
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:9055809"
FT                   /id="VSP_025904"
FT   VAR_SEQ         641
FT                   /note="C -> K (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:9055809"
FT                   /id="VSP_025905"
FT   VAR_SEQ         642..1068
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:9055809"
FT                   /id="VSP_025906"
FT   VARIANT         145
FT                   /note="A -> G (in dbSNP:rs11967003)"
FT                   /id="VAR_032572"
FT   VARIANT         320
FT                   /note="V -> M (in dbSNP:rs35331811)"
FT                   /evidence="ECO:0000269|PubMed:9205841"
FT                   /id="VAR_032573"
FT   VARIANT         424
FT                   /note="E -> K (in dbSNP:rs34016544)"
FT                   /id="VAR_032574"
FT   VARIANT         452
FT                   /note="S -> C (in dbSNP:rs34298086)"
FT                   /id="VAR_032575"
FT   VARIANT         495
FT                   /note="E -> K (in dbSNP:rs35514577)"
FT                   /id="VAR_032576"
FT   VARIANT         520
FT                   /note="R -> C (in dbSNP:rs35780910)"
FT                   /id="VAR_032577"
FT   VARIANT         566..569
FT                   /note="Missing (in DFNA21; does not affect expression
FT                   level; contrary to wild-type, does not rescue the
FT                   morphological defects observed in hair cells of knockout
FT                   mice, which include hair bundle polarity and cohesion and
FT                   length of stereocilia; dbSNP:rs760676508)"
FT                   /evidence="ECO:0000269|PubMed:32631815"
FT                   /id="VAR_087100"
FT   VARIANT         868
FT                   /note="R -> Q (in dbSNP:rs9461073)"
FT                   /evidence="ECO:0000269|PubMed:9205841"
FT                   /id="VAR_062193"
FT   MUTAGEN         21
FT                   /note="S->A: Reduces phosphorylation, interaction with
FT                   HDAC6, YWHAB and 14-3-3 proteins, localization at the front
FT                   of the neutrophil upon chemokine stimulation and prevents T
FT                   cell proliferation inhibition; when associated with A-37;
FT                   A-341; A-523 and A-585 (isoform 2)."
FT                   /evidence="ECO:0000269|PubMed:25588844,
FT                   ECO:0000269|PubMed:27556504"
FT   MUTAGEN         37
FT                   /note="S->A: Reduces phosphorylation, interaction with
FT                   HDAC6, YWHAB and 14-3-3 proteins, localization at the front
FT                   of the neutrophil upon chemokine stimulation and prevents T
FT                   cell proliferation inhibition; when associated with A-21;
FT                   A-341; A-523 and A-585 (isoform 2)."
FT                   /evidence="ECO:0000269|PubMed:25588844,
FT                   ECO:0000269|PubMed:27556504"
FT   MUTAGEN         151..152
FT                   /note="RL->AA: Inhibits interaction with RHOA and does not
FT                   prevent T cell proliferation inhibition; in isoform 2."
FT                   /evidence="ECO:0000269|PubMed:25588844,
FT                   ECO:0000269|PubMed:27556504"
FT   MUTAGEN         155..156
FT                   /note="GA->RR: Inhibits interaction with RHOA; in isoform
FT                   2."
FT                   /evidence="ECO:0000269|PubMed:25588844,
FT                   ECO:0000269|PubMed:27556504"
FT   MUTAGEN         341
FT                   /note="S->A: Reduces phosphorylation, interaction with
FT                   HDAC6, YWHAB and 14-3-3 proteins, localization at the front
FT                   of the neutrophil upon chemokine stimulation and prevents T
FT                   cell proliferation inhibition; when associated with A-21;
FT                   A-37; A-523 and A-585 (isoform 2)."
FT                   /evidence="ECO:0000269|PubMed:25588844,
FT                   ECO:0000269|PubMed:27556504"
FT   MUTAGEN         523
FT                   /note="S->A: Reduces phosphorylation, interaction with
FT                   HDAC6, YWHAB and 14-3-3 proteins, localization at the front
FT                   of the neutrophil upon chemokine stimulation and prevents T
FT                   cell proliferation inhibition; when associated with A-21;
FT                   A-37; A-341 and A-585 (isoform 2)."
FT                   /evidence="ECO:0000269|PubMed:25588844,
FT                   ECO:0000269|PubMed:27556504"
FT   MUTAGEN         585
FT                   /note="S->A: Reduces phosphorylation, interaction with
FT                   HDAC6, YWHAB and 14-3-3 proteins, localization at the front
FT                   of the neutrophil upon chemokine stimulation and prevents T
FT                   cell proliferation inhibition; when associated with A-21;
FT                   A-37; A-341 and A-523 (isoform 2)."
FT                   /evidence="ECO:0000269|PubMed:25588844,
FT                   ECO:0000269|PubMed:27556504"
FT   CONFLICT        13
FT                   /note="P -> A (in Ref. 1; AAC51134)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1068 AA;  118519 MW;  CCA7DEB3A66F36AA CRC64;
     MLVGSQSFSP GGPNGIIRSQ SFAGFSGLQE RRSRCNSFIE NSSALKKPQA KLKKMHNLGH
     KNNNPPKEPQ PKRVEEVYRA LKNGLDEYLE VHQTELDKLT AQLKDMKRNS RLGVLYDLDK
     QIKTIERYMR RLEFHISKVD ELYEAYCIQR RLQDGASKMK QAFATSPASK AARESLTEIN
     RSFKEYTENM CTIEVELENL LGEFSIKMKG LAGFARLCPG DQYEIFMKYG RQRWKLKGKI
     EVNGKQSWDG EETVFLPLIV GFISIKVTEL KGLATHILVG SVTCETKELF AARPQVVAVD
     INDLGTIKLN LEITWYPFDV EDMTASSGAG NKAAALQRRM SMYSQGTPET PTFKDHSFFR
     WLHPSPDKPR RLSVLSALQD TFFAKLHRSR SFSDLPSLRP SPKAVLELYS NLPDDIFENG
     KAAEEKMPLS LSFSDLPNGD CALTSHSTGS PSNSTNPEIT ITPAEFNLSS LASQNEGMDD
     TSSASSRNSL GEGQEPKSHL KEEDPEEPRK PASAPSEACR RQSSGAGAEH LFLENDVAEA
     LLQESEEASE LKPVELDTSE GNITKQLVKR LTSAEVPMAT DRLLSEGSVG GESEGCRSFL
     DGSLEDAFNG LLLALEPHKE QYKEFQDLNQ EVMNLDDILK CKPAVSRSRS SSLSLTVESA
     LESFDFLNTS DFDEEEDGDE VCNVGGGADS VFSDTETEKH SYRSVHPEAR GHLSEALTED
     TGVGTSVAGS PLPLTTGNES LDITIVRHLQ YCTQLVQQIV FSSKTPFVAR SLLEKLSRQI
     QVMEKLAAVS DENIGNISSV VEAIPEFHKK LSLLSFWTKC CSPVGVYHSP ADRVMKQLEA
     SFARTVNKEY PGLADPVFRT LVSQILDRAE PLLSSSLSSE VVTVFQYYSY FTSHGVSDLE
     SYLSQLARQV SMVQTLQSLR DEKLLQTMSD LAPSNLLAQQ EVLRTLALLL TREDNEVSEA
     VTLYLAAASK NQHFREKALL YYCEALTKTN LQLQKAACLA LKILEATESI KMLVTLCQSD
     TEEIRNVASE TLLSLGEDGR LAYEQLDKFP RDCVKVGGRH GTEVATAF
//
